Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris.
Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, Sinclair R, Neale A, Arora P, Sugerman PB, Shi G, Werth VP, Caux F, Joly P; BELIEVE Trial Investigators.
Murrell DF, et al. Among authors: stavropoulos p.
J Eur Acad Dermatol Venereol. 2022 Jun 10. doi: 10.1111/jdv.18318. Online ahead of print.
J Eur Acad Dermatol Venereol. 2022.
PMID: 35686647
No abstract available.